Roche CEO Schwan flags more biopharma partnering ahead

Roche CEO Severin Schwan

Back at the big JP Morgan conference in San Francisco in January, Roche's ($RHHBY) big $1 billion-plus tie-up with Foundation Medicine made it clear to the most casual biopharma observer that the pharma giant plans to partner more frequently as it builds up its pipeline and expands on its diagnostics business. And in case anyone missed that signal, CEO Severin Schwan just added his personal endorsement of the collaboration strategy. "We are open for possible forms of collaboration with external parties," Schwan told reporters today, according to a report from Reuters. "Partnering is absolutely fundamental." Story

Suggested Articles

The deal gives J&J a stake in the development and commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.

Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.

Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.